Nel ASA's October Date With Destiny: A Vacant CEO Office and a Pivotal Earnings Report

Nel ASA will report Q3 on Oct 21 amid a 48% stock drop and an unresolved CEO succession, with PEM growth offset by alkaline weakness.

The Norwegian hydrogen specialist Nel ASA now has a firm date on the calendar that could determine whether its recent share-price slide is a buying opportunity or a warning sign. The company has confirmed it will publish third-quarter results on October 21, with fourth-quarter figures slated for February 18, 2027. For a stock that has shed roughly 48 percent of its value since late May, that reporting date has taken on outsized significance.

The wait, however, is complicated by an unresolved question hanging over the Oslo-based company: who will be in charge when those numbers land? Håkon Volldal, who has led Nel since July 2022 and reshaped its strategy, product portfolio, and key partnerships, is serving out a six-month notice period that began in mid-June. The board has yet to name a successor, leaving investors to weigh operational momentum against leadership uncertainty.

An Order Book in Transition

The stakes are heightened by the diverging fortunes of Nel's two core businesses. Second-quarter order intake surged 224 percent year-over-year to 230 million Norwegian kroner, with a remarkable 96 percent of that total coming from the PEM segment. The PEM backlog climbed to 990 million kroner, up 147 million from the previous quarter and reflecting 31 percent sequential growth in that division.

The alkaline business tells a different story. That segment saw revenues fall 14 percent year-over-year, while its order backlog contracted by 46 million kroner quarter-over-quarter — evidence that the PEM boom is not lifting all boats. Group revenue slipped 12 percent to 153 million kroner in the same period, and EBITDA swung to a negative 155 million kroner after a 70 million kroner charge related to a settlement with Iwatani.

That Iwatani hit serves as a reminder that contractual disputes can dent results even when the underlying business is expanding. Still, the company's cash position of 1.328 billion kroner provides breathing room — though investors are increasingly asking whether a full order book can translate into profitable growth before a new chief executive potentially recalibrates priorities.

A Share Price That Tells Its Own Story

The market has already rendered its verdict on the near-term outlook. Nel's shares last changed hands at around 0.1916 to 0.1918 euros, roughly 48 percent below the 52-week high of 0.3655 euros reached on May 25. The most recent session brought a modest 0.9 percent gain, but technical observers describe the stock as trapped in a persistent downtrend that has been in place for weeks — a slide that has unfolded without any fresh negative operational news from the company itself.

Market capitalization now stands at approximately 352.64 million euros, and the relative strength index sits at 40.5, suggesting neutral-to-weak momentum rather than oversold conditions. Analyst sentiment has been similarly cautious: JPMorgan trimmed its price target on Nel from 2.90 to 1.80 Norwegian kroner in early August while maintaining a "Neutral" rating — a call that predates the latest weakness but underscores how skepticism toward the stock was already entrenched.

What Could Break the Stalemate

For bulls, the case rests on the PEM segment's trajectory and the financial runway supporting it. Nel has secured an EU grant of 118 million kroner to commercialize its next-generation pressurized alkaline electrolyzer, and capacity expansion at the Herøya facility is planned through 2026 and 2027. A 13 percent reduction in headcount year-over-year also signals cost discipline that could pay dividends during the recovery phase.

Should the board present an experienced successor who commits to continuing Volldal's portfolio overhaul, confidence in strategic continuity could be reinforced. The risk, of course, is that a prolonged search — or a new leader with different priorities — delays investment decisions and unsettles the market further.

The October 21 report will provide the first concrete test of whether the second-quarter order momentum has carried through and whether leadership clarity has emerged by then. Until that day arrives, the succession question remains the invisible but decisive factor shaping how investors value the stock — and whether the current share price reflects genuine operational progress or simply a market waiting for answers.